Navigation Links
Fixed Dosed Combination Agents and Novel Antihypertensives Are Expected to Face Tougher Formulary Restrictions
Date:4/28/2009

Longitudinal Data Trends Suggest These Agents Will Face Greater Use of Step Therapy Restrictions and Less Access on Tier 2 on Commercial Health Plans, According to a New Report from HealthLeaders-InterStudy and Fingertip Formulary

NASHVILLE, Tenn. and GLEN ROCK, N.J., April 28 /PRNewswire/ -- HealthLeaders-InterStudy and Fingertip Formulary find that fixed dosed combination agents and novel antihypertensives are expected to face tougher formulary restrictions. According to the new Formulary Forum report entitled Formulary Advantages in Hypertension: Past and Future Shifts in Tier Placement of Angiotensin II Receptor Antagonists, Single Pill Fixed-Dose Combinations and Novel Agents, step therapy restrictions are becoming more common in commercial health plans across all classes of antihypertensives, suggesting fixed dosed combination agents and novel antihypertensives will face less access on Tier 2 on commercial health plans.

The report notes that although the number of commercial health plans placing step restrictions on angiotensin II receptor antagonists is relatively stable, a growing number of covered lives are subject to a step therapy restriction. Meanwhile, the number of commercial health plans placing prior authorization restrictions on antihypertensives has decreased over the past year.

"By and large, more agents are subject to prior authorization restrictions with more commercial health plans than are subject to step therapy restrictions, but we are seeing step therapy restrictions becoming increasingly common," said Michael Malecki, Ph.D., product manager, Formulary Forum. "The changing landscape of formulary controls in the hypertension market means that managed care marketing and sales analytics groups must track this newly-important performance metric."

About Formulary Advantages in Hypertension: Past and Future Shifts in Tier Placement of Angiotensin II Receptor Antagonists, Single Pill Fixed-Dose Combinations and Novel Agents

The new Formulary Forum report is based on a survey of 50 pharmacy directors who control national, regional and state-level managed care organizations, as well as historical formulary data from Fingertip Formulary. Answers were segmented by type of plan to illustrate variances in strategy by size of plan. The easy-to-use PowerPoint format allows easy visualization of data and easy incorporation of material into presentations.

About Fingertip Formulary

Fingertip Formulary (www.FingertipFormulary.com), the leading provider of access to and insight into formulary data in the United States, offers comprehensive formulary data covering commercial, Medicaid, Medicare and PBM plans, among others. The company offers a variety of unique data and marketing solutions for the pharmaceutical industry, consultants and healthcare providers that provide access to and insight into formulary data. Fingertip Formulary is a Decision Resources, Inc. company.

About HealthLeaders-InterStudy

HealthLeaders-InterStudy, a Decision Resources, Inc. company, is the authoritative source for managed care data, analysis and news. For more information, please visit www.HL-ISY.com.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Both HealthLeaders-InterStudy and Fingertip Formulary are Decision Resources, Inc. companies. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE HealthLeaders-InterStudy
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Conseco Completes Divestiture of Old Block of Fixed and Equity-Indexed Annuities
2. New Human Services Website Details Economic Importance of Providers, Warns of Looming Crisis if System is Not Fixed Immediately
3. AAHSA Survey and Certification Task Force: The System Is Broken and Cant Be Fixed
4. Nursing Home Task Force Says, The System Is Broken and Cant Be Fixed
5. New Study Provides Benchmarks for Fixed-Dose Combination (FDC) Drug Development
6. AARP Responds to Senator Grassley, Conducts Comprehensive Review of Marketing of Fixed Benefit Indemnity Products
7. Best Practice Database Provides Benchmarks for Fixed-Dose Combination (FDC) Drug Development
8. Allsup Finds Healthcare Costs Consuming Larger Part of Fixed Incomes
9. New Fixed Blade Axial dc Fan From NMB
10. 70% of Contact Lens Cases are Contaminated and Nearly 1 in 4 are Never Replaced - a Serious Problem Eye Doctors Want Fixed, WatchDog Group Reports
11. Promising drug combination may help those with ocular melanoma that has spread
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... RICHEY, Fla. (PRWEB) , ... April 24, 2017 ... ... and Prevention (CDC), rising prescription opioid overdose deaths now claim the lives of ... slashed its civil case filings against drug manufacturers, distributors, pharmacies and prescribers by ...
(Date:4/24/2017)... ... April 24, 2017 , ... Pitavastatin, a relatively ... it is not known to have significant interactions with antiretroviral therapy (ART). ... cholesterol levels and dampen inflammation in the bloodstream. , While lowering cholesterol and ...
(Date:4/24/2017)... ... April 24, 2017 , ... Donna Parker, L. Ac. reads all sorts of ... of them to be very practical. She wanted to write a guide/workbook that would ... their health. It prompted her in writing “ A Clear Path to a Vibrant ...
(Date:4/24/2017)... ... April 24, 2017 , ... “The Saint with Trin, ... Trin, and Omega Station” is the creation of published author, Chris Jackson. Chris ... where he works in the Dallas Independent School District teaching English. He is heavily ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... of next generation neuro-thrombectomy systems for the treatment of Acute Ischemic Stroke (AIS), ... ANCD BRAIN device as the product advances towards regulatory and clinical phases. , ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... the "Global Biosimilar Pipeline and Market Prospects: Addressing ... report to their offering. ... "Global Biosimilar Pipeline and Market ... by Design" provides an in-depth assessment of the current ...
(Date:4/20/2017)... , April 20, 2017  CVS Pharmacy, the ... unveiled a new store design to enhance the ... healthier food, health-focused products and expanded beauty selections ... help customers discover new offerings. Together with its ... evolution of the customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... , April 20, 2017 Research ... Pharmacogenomics Market Size, Market Share, Application Analysis, Regional Outlook, Growth ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 ... Mn by 2024, expanding at a CAGR of 5.6% from ...
Breaking Medicine Technology: